FIRST LIVER TRANSPLANT WITH STEEN SOLUTION™ PERFORMED DURING THE QUARTER

THIRD QUARTER 2015 (JUL – SEP)

 • Net sales in the quarter amounted to SEK 26.6 (22.4) million, corresponding
to an increase of 19 percent.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK
4.2 (3.4) million, corresponding to an EBITDA margin of 16 percent.
• Net income amounted to SEK 1.1 (1.5) million, resulting in earnings per share
of SEK 0.05 (0.07). The figures are affected by amortization and depreciation of
SEK 2.8 (1.2) million.
• Cash flow from operating activities was SEK 2.8 (4.3) million.
• Net sales of non-Durable goods* in the quarter amounted to SEK 24.3 (21.0)
million, corresponding to an increase of 16 percent in SEK. Sales of non-Durable
goods increased by 3 percent in local currency.
• Products for warm perfusion (STEEN Solution™ and products related to the use
of the XPS™) accounted for 22 (25) percent of total sales of non-Durable goods.
In total, products for warm perfusion and the XPS™ accounted for 29 (30) percent
of total sales.
• During the quarter rolling 12 month sales amounted to SEK 113 million. Rolling
12 month sales excluding capital goods amounted to SEK 102 million and were
above SEK 100 million for the first time.
• The first clinical liver transplant with a liver perfused with STEEN Solution™
was performed in Toronto, Canada. In total seven successful liver transplants
have been performed as part of a phase 1 clinical trial.
• The company has taken a policy decision to apply for a listing on Nasdaq
Stockholm’s main list during 2016. This will entail one-time expenses for the
company which will be recognized and reported on an ongoing basis during the
coming year.

THE PERIOD 2015 (JAN – SEP)

 • Net sales in the period amounted to SEK 87.6 (59.2) million, corresponding to
an increase of 48 percent.
• Operating income before depreciation and amortization (EBITDA) excluding one
-time expenses amounted to SEK 11.3 (8.3) million, corresponding to an EBITDA
margin of 13 percent.
• Net income amounted to SEK 1.4 (4.1) million, resulting in earnings per share
of SEK 0.06 (0.20). The figures are affected by amortization and depreciation of
SEK 8.5 (1.9) million.
• Cash flow from operating activities was SEK 5.7 (1.7) million.
• Net sales of non-Durable goods* in the period amounted to SEK 76.8 (57.7)
million, corresponding to an increase of 33 percent in SEK. Sales of non-Durable
goods increased by 15 percent in local currency.
• Products for warm perfusion (STEEN Solution™ and products related to the use
of the XPS™) accounted for 29 (24) percent of total sales of non-Durable goods.
In total, products for warm perfusion and the XPS™ accounted for 38 (26) percent
of total sales.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

• The AKH University Hospital in Vienna, Austria, which is the world’s second
largest lung transplant clinic, has decided to use the XPS™. Delivery and
installation of the XPS™ took place in October.
• When the report was published 22 clinics have access to the XPS™, of which 18
are located in the US.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on
Friday, October 23, 2015. Telephone: +44 (0) 1452 555566, enter code 55238585.

October 23, 2015
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO

* Durable goods are sales revenues from the XPS™.
For further information please contact:
Christoffer Rosenblad, CFO, 1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on October 23, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com